Enzystal-P, 20 pcs.

Enzystal-P is an enzyme remedy.

It contains pancreatic enzymes – amylase, lipase and proteases that facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine.

In diseases of the pancreas, it compensates the insufficiency of its external secretory function and improves the digestive process.

Indications

Insufficiency of the exocrine function of the pancreas (including in chronic pancreatitis, cystic fibrosis).
Chronic inflammatory-dystrophic diseases of the stomach, intestines, liver, gall bladder; conditions after resection or irradiation of these organs, accompanied by impaired digestion of food, flatulence, diarrhea (as part of combination therapy).
To improve the digestion of food in patients with normal gastrointestinal function in case of errors in nutrition, as well as in cases of disorders of chewing function, forced long-term immobilization, and a sedentary lifestyle.
Preparation for x-ray and ultrasound examination of the abdominal organs.

Pharmacological effect

Enzistal-P is an enzyme agent.

Contains pancreatic enzymes – amylase, lipase and proteases, which facilitate the digestion of carbohydrates, fats and proteins, which facilitates their more complete absorption in the small intestine.

In diseases of the pancreas, it compensates for the insufficiency of its exocrine function and helps improve the digestion process.

Special instructions

Use in the acute phase of chronic pancreatitis is not recommended.

For cystic fibrosis, the dose should be adequate to the amount of enzymes that is necessary for the absorption of fats, taking into account the quality and quantity of food consumed.

For cystic fibrosis, the use of pancreatin in doses of more than 10,000 units/kg/day (in terms of lipase) is not recommended due to the increased risk of developing strictures (fibrous colonopathy) in the ileocecal region and in the ascending colon.

With high lipase activity contained in pancreatin, the likelihood of developing constipation in children increases. Increasing the dose of pancreatin in this category of patients should be carried out gradually.

Digestive system disorders may occur in patients with hypersensitivity to pancreatin, or in patients with meconium ileus or a history of intestinal resection.

Active ingredient

Pancreatin

Composition

1 enteric-coated tablet contains:

active ingredient:

pancreatin 116.17 mg

Pregnancy

The safety of using pancreatin during pregnancy has not been sufficiently studied. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

Experimental studies have shown that pancreatin does not have a teratogenic effect.

Use in children

Application is possible according to the dosage regimen. With high lipase activity contained in pancreatin, the likelihood of developing constipation in children increases.

Contraindications

Acute pancreatitis, hypersensitivity to pancreatin.

Side Effects

When used in average therapeutic doses, side effects are observed in less than 1%.

From the digestive system: in some cases – diarrhea, constipation, discomfort in the stomach, nausea. The cause-and-effect relationship between the development of these reactions and the action of pancreatin has not been established, because These phenomena refer to symptoms of exocrine pancreatic insufficiency.

Allergic reactions: in some cases – skin manifestations.

From the metabolic side: with long-term use in high doses, the development of hyperuricosuria is possible; in excessively high doses, an increase in the level of uric acid in the blood plasma.

Other: when using pancreatin in high doses in children, perianal irritation may occur.

Interaction

When used simultaneously with antacids containing calcium carbonate and/or magnesium hydroxide, the effectiveness of pancreatin may be reduced.

With simultaneous use, it is theoretically possible to reduce the clinical effectiveness of acarbose.

With simultaneous use of iron supplements, a decrease in iron absorption is possible.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Torrent Pharmaceuticals Ltd, India